Legend Biotech Corp ADR (LEGN) Stock Price, Quote & News

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 317 5050

Website: legendbiotech.com

Address:

2101 Cottontail Lane, Somerset, United States

guggles Jun. 5 at 12:05 AM

$LEGN 40$ next week.

0 · Reply

Doozio Jun. 4 at 11:05 PM

Dips into a $LEGN of huckleberries are a 🎁 as an $ARRY of them begin rocking with Roger ONTO 🐒🍌🧠⏰♾️

0 · Reply

z_guy Jun. 4 at 8:56 PM

$LEGN why you’re selling …

0 · Reply

WolfofWallasey Jun. 4 at 2:24 PM

Cashed out a lot of profit and capital from $BGDE (thank you and I’ll be back) Stopped chasing $AIOS for now but watching Rebalanced my capital across my two new babies $LEGN and $RXRX Been in heavy on $LEGN since it was $28 so v happy and holding …. Seems to be inevitable this goes a lot higher . Monster drug and revenue is undeniable $RXRX is my new squeeze . Sexy . Just bags of potential and I searched their institutional investors …. Absolute 🔥 check that out for a list. Feel good about these two as my new girls . Just need to keep working to add a bit more to them each month

1 · Reply

supplySHOCK Jun. 4 at 9:10 AM

$TLYS $GEMI $LEGN $YINN atchl

0 · Reply

Randomizer123 Jun. 4 at 12:13 AM

$LEGN RBC Capital analyst praising the Legend Biotech’s In Vivo CAR-T data for its blockbuster potential.

0 · Reply

supplySHOCK Jun. 3 at 8:59 PM

$FIGR $RIOT $SATL $LEGN sharp

0 · Reply

GeniusLoci Jun. 3 at 8:10 PM

$LEGN UBS analyst Ashwani Verma maintains Legend Biotech with a Buy and raises the price target from $31 to $49

0 · Reply

prismmarketview Jun. 3 at 7:08 PM

CAR-T is moving beyond cancer, and the next frontier is autoimmune disease. Legend Biotech's first in vivo data shows the modality maturing. The names actually positioned for the shift are smaller: Cabaletta, Kyverna, and Nkarta. $LEGN $CABA $KYTX $NKTX https://prismmarketview.com/cell-therapy-transformed-cancer-care-can-it-reset-the-immune-system/

0 · Reply

DCZ Jun. 3 at 5:45 PM

$LEGN hopefully we are consolidating here before we take the next leg up into the 40’s

1 · Reply

Legend Biotech price target raised to $49 from $31 at UBS

2026-06-03T10:16:18.000Z - 1 day ago

Legend Biotech price target raised to $65 from $50 at H.C. Wainwright

2026-06-02T17:21:37.000Z - 2 days ago

This Is Why Legend Biotech Stock (LEGN) Was Up Today

2026-06-02T16:18:47.000Z - 2 days ago

Legend Biotech rises 29.5%

2026-06-02T14:06:38.000Z - 2 days ago

Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress

Jun 2, 2026, 9:31 AM EDT - 2 days ago

Legend's experimental cell therapy shows promise in blood cancer patients

Jun 2, 2026, 9:30 AM EDT - 2 days ago

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

2026-06-01T16:05:07.000Z - 3 days ago

Legend Biotech presents first-in-human LB2102 results in solid tumors

Jun 1, 2026, 10:00 AM EDT - 3 days ago

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

May 31, 2026, 7:00 PM EDT - 4 days ago

Legend Biotech Transcript: American Society of Clinical Oncology (ASCO) Annual Meeting 2026

May 21, 2026, 5:00 PM EDT - 14 days ago

Legend Biotech Announces Presentations at ASCO 2026

2026-05-13T16:55:07.000Z - 22 days ago

Legend Biotech price target lowered to $48 from $49 at Morgan Stanley

2026-05-13T15:57:12.000Z - 22 days ago

Legend Biotech price target raised to $29 from $21 at TD Cowen

2026-05-13T15:00:09.000Z - 22 days ago

Legend Biotech price target raised to $64 from $62 at RBC Capital

2026-05-12T13:11:11.000Z - 23 days ago

Legend Biotech reports Q1 EPS (3c), consensus (17c)

May 12, 2026, 8:00 AM EDT - 23 days ago

Legend Biotech Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 23 days ago

Legend Biotech Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 23 days ago

Legend Biotech Slides: Q1 2026

May 12, 2026, 7:00 AM EDT - 23 days ago

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

May 4, 2026, 8:00 AM EDT - 4 weeks ago

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

2026-03-11T12:52:50.000Z - 3 months ago

Legend Biotech price target lowered to $49 from $50 at Morgan Stanley

2026-03-11T12:39:24.000Z - 3 months ago

Legend Biotech price target lowered to $62 from $66 at RBC Capital

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Legend Biotech Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Legend Biotech Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Legend Biotech Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Legend Biotech Slides: Q4 2025

2026-03-10T11:06:40.000Z - 3 months ago

Legend Biotech reports Q4 adjusted EPS 1c vs. (15c) last year

2026-03-10T11:05:54.000Z - 3 months ago

Legend Biotech sees cash runway beyond 2026

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

2026-03-09T13:06:19.000Z - 3 months ago

Legend Biotech selloff brings favorable risk/reward, says Deutsche Bank

Feb 24, 2026, 8:00 AM EST - 3 months ago

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

2026-02-23T15:07:34.000Z - 3 months ago

Legend Biotech rises 16.6%

2026-02-12T11:46:34.000Z - 4 months ago

Legend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn

2026-02-04T10:50:59.000Z - 4 months ago

Legend Biotech price target lowered to $80 from $90 at Barclays

Jan 14, 2026, 12:00 PM EST - 5 months ago

Legend Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 5 months ago

Legend Biotech Slides: 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 3:31 PM EST - 6 months ago

Cancer Study Buoys These Small Biotechs

ACLX TERN

Dec 6, 2025, 2:00 PM EST - 6 months ago

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Dec 3, 2025, 7:00 AM EST - 6 months ago

Legend Biotech Slides: Corporate presentation

Nov 13, 2025, 12:08 PM EST - 7 months ago

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Nov 12, 2025, 8:00 AM EST - 7 months ago

Legend Biotech Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Legend Biotech Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Legend Biotech Slides: Q3 2025

Nov 3, 2025, 11:05 AM EST - 7 months ago

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 29, 2025, 8:00 AM EDT - 7 months ago

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

Oct 10, 2025, 6:36 PM EDT - 8 months ago

US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy

JNJ

Sep 9, 2025, 4:05 PM EDT - 9 months ago

Legend Biotech Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:00 AM EDT - 9 months ago

Legend Biotech Slides: Corporate Presentation

Aug 18, 2025, 8:00 AM EDT - 10 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Legend Biotech Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Legend Biotech Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Legend Biotech Slides: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

Jul 1, 2025, 10:00 AM EDT - 1 year ago

Legend Biotech Slides: Corporate Presentation

Jun 4, 2025, 6:10 PM EDT - 1 year ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM VRNA

Jun 3, 2025, 10:45 AM EDT - 1 year ago

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

May 22, 2025, 5:15 PM EDT - 1 year ago

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q1 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Annual report: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q4 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

Jan 14, 2025, 6:45 PM EST - 1 year ago

Legend Biotech Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Legend Biotech Slides: FY 2025

Dec 19, 2024, 8:01 AM EST - 1 year ago

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

$CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma$

Dec 9, 2024, 7:35 PM EST - 1 year ago

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Dec 8, 2024, 11:00 PM EST - 1 year ago

Legend Biotech Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Slides: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 5, 2024, 9:10 AM EST - 1 year ago

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Sep 27, 2024, 4:35 PM EDT - 1 year ago

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Sep 24, 2024, 9:00 AM EDT - 1 year ago

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Sep 4, 2024, 2:35 PM EDT - 1 year ago

Legend Biotech Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q2 2024

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q2 2024

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q2 2024

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Jul 26, 2024, 7:00 AM EDT - 2 years ago

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

Jun 6, 2024, 10:30 AM EDT - 2 years ago

Legend Biotech Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 4:00 PM EDT - 2 years ago

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

May 31, 2024, 3:00 AM EDT - 2 years ago

Legend Biotech Slides: Corporate Presentation

May 29, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 2 years ago

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

May 13, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Earnings Call Transcript: Q1 2024

May 13, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Earnings release: Q1 2024

May 13, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Slides: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

guggles Jun. 5 at 12:05 AM

$LEGN 40$ next week.

0 · Reply

Doozio Jun. 4 at 11:05 PM

Dips into a $LEGN of huckleberries are a 🎁 as an $ARRY of them begin rocking with Roger ONTO 🐒🍌🧠⏰♾️

0 · Reply

z_guy Jun. 4 at 8:56 PM

$LEGN why you’re selling …

0 · Reply

WolfofWallasey Jun. 4 at 2:24 PM

1 · Reply

supplySHOCK Jun. 4 at 9:10 AM

$TLYS $GEMI $LEGN $YINN atchl

0 · Reply

Randomizer123 Jun. 4 at 12:13 AM

$LEGN RBC Capital analyst praising the Legend Biotech’s In Vivo CAR-T data for its blockbuster potential.

0 · Reply

supplySHOCK Jun. 3 at 8:59 PM

$FIGR $RIOT $SATL $LEGN sharp

0 · Reply

GeniusLoci Jun. 3 at 8:10 PM

$LEGN UBS analyst Ashwani Verma maintains Legend Biotech with a Buy and raises the price target from $31 to $49

0 · Reply

prismmarketview Jun. 3 at 7:08 PM

0 · Reply

DCZ Jun. 3 at 5:45 PM

$LEGN hopefully we are consolidating here before we take the next leg up into the 40’s

1 · Reply

Zardiw Jun. 3 at 4:45 PM

$TDTH - up or down? What's your read on this one? Others on the radar: $PUSA $PMI $LEGN Full scanner at: https://DDAmanda.com #DDAmanda

0 · Reply

Greenspam Jun. 3 at 3:43 PM

$LEGN "Given the recent analyst rating and the substantial undervaluation indicated by the GF Value™, Legend Biotech presents an intriguing opportunity for investors." in https://www.gurufocus.com/news/8898560/legn-maintained-by-hc-wainwright-co-price-target-raised-to-65

0 · Reply

GeniusLoci Jun. 3 at 3:25 PM

$LEGN HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech with a Buy and raises the price target from $50 to $65

0 · Reply

KY3000 Jun. 3 at 3:15 PM

$LEGN if BO it’s going to be tricky. Washington starting to move against Chinese biotech. 1/2 owned by genscript(AKA Xi). Novartis might have a smoother process.

1 · Reply

victorgn Jun. 3 at 2:53 PM

$LEGN $55$

0 · Reply

Greenspam Jun. 3 at 1:50 PM

$LEGN SUNDAY 14th June! "Its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy will be presented during a late-breaking session at the European Hematology Association (EHA) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden.

0 · Reply

Greenspam Jun. 3 at 1:42 PM

$LEGN Or even more?

0 · Reply

IsabellaDC Jun. 3 at 1:33 PM

$LEGN :)

0 · Reply

Greenspam Jun. 3 at 1:25 PM

$LEGN

0 · Reply

IsabellaDC Jun. 3 at 1:23 PM

$LEGN May continue. Down premarket but very unsignificant volume.

0 · Reply

Randomizer123 Jun. 3 at 12:59 PM

$LEGN Oppenheimer’s Biliouris will not rest until he sees the BO through 😀

0 · Reply

Randomizer123 Jun. 3 at 12:40 PM

$LEGN Legend's experimental cell therapy shows promise in blood cancer patients | Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/legends-experimental-cell-therapy-shows-promise-blood-cancer-patients-2026-06-02/

0 · Reply

Market Cap	6.68B
Revenue (ttm)	1.03B
Net Income (ttm)	-296.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	1,261.91
Profit Margin	-28.85%
Debt to Equity Ratio	0.27

Volume	3,415,000
Avg Vol	2,582,410
Day's Range	N/A - N/A
Shares Out	185.74M
Stochastic %K	74%
Beta	0.35
Analysts	Strong Sell
Price Target	$57.33